Source: http://www.google.com/patents/US8057822?dq=6,034,652
Timestamp: 2015-08-04 00:01:31
Document Index: 34720993

Matched Legal Cases: ['Application No. 2', 'Application No. 2', 'Application No. 00', 'Application No. 00', 'Application No. 00', 'Application No. 00', 'Application No. 00']

Patent US8057822 - Modified exendins and exendin agonists - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsNovel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods...http://www.google.com/patents/US8057822?utm_source=gb-gplus-sharePatent US8057822 - Modified exendins and exendin agonistsAdvanced Patent SearchPublication numberUS8057822 B2Publication typeGrantApplication numberUS 11/174,089Publication dateNov 15, 2011Filing dateJun 30, 2005Priority dateApr 30, 1999Fee statusPaidAlso published asUS6924264, US7608692, US7683030, US7691963, US8445647, US8951962, US20050267034, US20080176802, US20080200390, US20080214467, US20120135922, US20140038891Publication number11174089, 174089, US 8057822 B2, US 8057822B2, US-B2-8057822, US8057822 B2, US8057822B2InventorsKathryn S. Prickett, Andrew A. YoungOriginal AssigneeAmylin Pharmaceuticals, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (50), Non-Patent Citations (144), Referenced by (4), Classifications (13), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetModified exendins and exendin agonists
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4179337Jul 28, 1977Dec 18, 1979Davis Frank FNon-immunogenic polypeptidesUS4766106Jan 25, 1988Aug 23, 1988Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugationUS5122614Apr 19, 1990Jun 16, 1992Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptidesUS5176918 *Dec 20, 1990Jan 5, 1993Jones Jeffry LTopical medicamentUS5214131Nov 26, 1991May 25, 1993Sumitomo Pharmaceuticals Company, LimitedPolyethylene glycol derivatives, modified peptides and production thereofUS5264372Mar 15, 1991Nov 23, 1993Amylin Pharmaceuticals, Inc.Receptor-based screening methods for amylin agonists and antagonistsUS5424286 *May 24, 1993Jun 13, 1995Eng; JohnExendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising sameUS5428128 *Sep 27, 1994Jun 27, 1995Mensi-Fattohi; NahlaSite specific synthesis of conjugated peptidesUS5686511Jun 28, 1996Nov 11, 1997The Valspar CorporationEsterifying epoxy resin with carboxyl polymer and quenchingUS5747639Mar 6, 1996May 5, 1998Amgen Boulder Inc.Use of hydrophobic interaction chromatography to purify polyethylene glycolsUS5824784 *Oct 12, 1994Oct 20, 1998Amgen Inc.N-terminally chemically modified protein compositions and methodsUS5839443May 16, 1996Nov 24, 1998The Trustees Of Columbia University In The City Of New YorkMethod for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulationUS6051557Apr 13, 1998Apr 18, 20001149336 Ontario Inc.Methods of enhancing functioning of the upper gastrointestinal tractUS6268343Feb 26, 1999Jul 31, 2001Novo Nordisk A/SDerivatives of GLP-1 analogsUS6284725Apr 30, 1999Sep 4, 2001Bionebraska, Inc.Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissueUS6376549Sep 17, 1998Apr 23, 2002Akesis Pharmaceuticals, Inc.Metforimin-containing compositions for the treatment of diabetesUS6429197Apr 30, 1999Aug 6, 2002Bionebraska, Inc.Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brainUS6451974 *Mar 13, 2000Sep 17, 2002Novo Nordisk A/SMethod of acylating peptides and novel acylating agentsUS6528486Jul 12, 2000Mar 4, 2003Zealand Pharma A/SPeptide agonists of GLP-1 activityUS6723530Feb 5, 1998Apr 20, 2004Amylin Pharmaceuticals, Inc.Polynucleotides encoding proexendin, and methods and uses thereofUS6753165Jan 14, 2000Jun 22, 2004Bolder Biotechnology, Inc.Methods for making proteins containing free cysteine residuesUS6767887 *Jun 5, 1997Jul 27, 2004Roche Diagnostics GmbhExendin analogues, processes for their preparation and medicaments containing themUS6872700 *Jan 14, 2000Mar 29, 2005Amylin Pharmaceuticals, Inc.Methods for glucagon suppressionUS6924264Apr 28, 2000Aug 2, 2005Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonistsUS6924624 *Jan 7, 2003Aug 2, 2005Robert Bosch GmbhMethod and apparatus for slowing the discharge process of a batteryUS6956026Jan 7, 1998Oct 18, 2005Amylin Pharmaceuticals, Inc.Use of exendins for the reduction of food intakeUS6982248May 9, 2001Jan 3, 2006Amylin Pharmaceuticals, Inc.Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissueUS7153825Mar 18, 2005Dec 26, 2006Amylin Pharmaceuticals, Inc.Methods for glucagon suppression using modified exendinsUS7189690Feb 11, 2004Mar 13, 2007Human Genome Sciences, Inc.Albumin fusion proteinsUS7226990Jun 21, 2001Jun 5, 2007Novo Nordisk A/SExtendin derivativesUS7259136Mar 5, 2002Aug 21, 2007Amylin Pharmaceuticals, Inc.Compositions and methods for treating peripheral vascular diseaseUS7271149Nov 29, 2001Sep 18, 2007Eli Lilly And CompanyGLP-1 fusion proteinsUS20010047084Jun 21, 2001Nov 29, 2001Knudsen Liselotte BjerreExtendin derivativesUS20020147131Sep 11, 2001Oct 10, 2002Coolidge Thomas R.Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused skeletal muscle tissueUS20050026834May 27, 2004Feb 3, 2005Bolder Biotechnology, Inc.Methods for making proteins containing free cysteine residuesUS20060030528Aug 5, 2005Feb 9, 2006Amylin Pharmaceuticals, Inc.Compositions and methods for treating peripheral vascular diseaseUS20070037750Oct 19, 2006Feb 15, 2007Amylin Pharmaceuticals, Inc.Methods for glucagon suppression using modified exendinsEP0619322A2Feb 10, 1994Oct 12, 1994Pfizer Inc.Prolonged delivery of peptidesWO1995007089A1Sep 9, 1994Mar 16, 1995Imutec CorpImmunomodulating compositions from bileWO1997046584A1Jun 5, 1997Dec 11, 1997Boehringer Mannheim GmbhExendin analogues, processes for their preparation and medicaments containing themWO1998005351A1Aug 8, 1997Feb 12, 1998Amylin Pharmaceuticals IncMethods for regulating gastrointestinal motilityWO1998008871A1Aug 22, 1997Mar 5, 1998Novo Nordisk AsGlp-1 derivativesWO1998030231A1Jan 7, 1998Jul 16, 1998Amylin Pharmaceuticals IncUse of exendins and agonists thereof for the reduction of food intakeWO1999007404A1Aug 6, 1998Feb 18, 1999Amylin Pharmaceuticals IncNovel exendin agonist compoundsWO1999025727A2Nov 13, 1998May 27, 1999Amylin Pharmaceuticals IncNovel exendin agonist compoundsWO1999025728A1Nov 13, 1998May 27, 1999Amylin Pharmaceuticals IncNovel exendin agonist compoundsWO1999043708A1Feb 25, 1999Sep 2, 1999Novo Nordisk AsGlp-1 derivatives of glp-1 and exendin with protracted profile of actionWO1999046283A1Mar 9, 1999Sep 16, 1999Bjarne Due LarsenPharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysisWO2000041548A2Jan 14, 2000Jul 20, 2000Amylin Pharmaceuticals IncMethods for glucagon suppressionWO2000066629A1Apr 28, 2000Nov 9, 2000Amylin Pharmaceuticals IncModified exendins and exendin agonists* Cited by examinerNon-Patent CitationsReference1Abuchowski, et al.; "Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Calalase"; Journal of Biological Chemistry, vol. 252; Issue 11:3582-3588 (Jun. 1977).2Alberts et al, Molecular Biology of the Cell, Third Edition, New York: Garland Publishing, p. G19 (1994).3Alberts et al., Molecular Biology of the Cell, Third Edition New York: Garland Publishing, pp. 589-591, 606-608 (1994).4Amylin Pharmaceuticals, Inc., Form 10-Q filed Aug. 7, 2007.5Amylin Pharmaceuticals, Inc., Form 10-Q filed Nov. 6, 2007.6 *Application note (no date) "molecular weight determinations of polymers and polysaccharides using the zetasizer nano system", pp. 1-3.7Barragan et al, Regulatory Peptides, 67:63-68 (1996).8Binder et al, Diabetes Care, 7:188-199 (1984).9Breton et al, Eur. J. Biochem., 231:563-569 (1995).10Broca et al., "Hydroxyisoleucine: Experimental evidence of Its Insulfinotropic and antidiabetic properties," Am. J. Physiol. 277:617 (1999).11Byetta Prescribing Information.12Byrne et al., "Lessons from human studes with glucagon-like peptide-1: Potential of the gut hormone for clinical use," in: Insufintropic Gut Hormones Glucagon-Like Peptide 1, Fehmann, HC Editor, Basel, Switzerland: Keroer, pp. 219-233 (1997).13Canadian Patent Application No. 2,372,214: Protest Udner Section 34.1 filed in Canadian Patent Application No. 2,372,214 (Jun. 26, 2009).14Capasso et al., J. Neuroedocrinology 220(Suppl. 1):39-46 (2008) "Gastrointestinal Regulation of Food Intake: General Aspects and Focus on Anandamide and Oleoylethyanolamide".15Catalog, Shearwater Polymers, Inc., Functionalized Biocompatible Polymers for Research, Polyethylene Glycol Derivatives, 1993.16Chen et al, Diabetes, vol. 48, Supplement 1, Abstract No. 1884 (May 1999).17Chen et al., "Tissue-specific Expression of Unique mRNAs that Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard," J. Biol. Chem. 272(7):4108-4115 (1997).18Chen, et al.; Diabetes, vol. 1, Supp. 1: A426, Abstract No. 1884 (May 1999).19 *Chicchi et al. (1997) Fluorescein-Trp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor. Peptides. vol. 18, pp. 319-321.20Cooper, The Cell: A Molecular Approach, ASM Press (Washington, DC), Sinauer Associates, Inc. (Sunderland, MA), pp. 296-298, 648 (1997).21Creutzfeldt et al., "Glucegonstatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucegon-Like Peptide 1(7-38) Amide in Type I Diabetic Patients," Diabetes Care 19(6):580-586 (1996).22Crowe et al., Methods Mol. Biol. 31:371-387 (1994).23D'Alessio et al., "Elimination of the Action of Glucagon-Like Peptide 1 Causes an Impalment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons," J. Clin. Invest. 97:133-38 (1996).24Davis et al, Peptide and Protein and Drug Delivery, Marcel Dekker, Inc., New York, pp. 831-864 (1991).25Declaration of Andrew Young attached to Request for Inter Partes Reexamination of US Patent No. 6,924,264.26Declaration of John Herich attached to Request for Inter Partes Reexamination of US Patent No. 6,924,264.27Declaration of Omar Quraishi attached to Request for Inter Partes Reexamination of US Patent No. 6,924,264.28 *Delgado et al. (1992) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. vol. 9, Nos. 3-4, pp. 249-304.29Delgado et al., "The Uses and Properties of PEG-Linked Proteins," Critical Reviews in Therapeutic Drug Carrier Systems 9(3,4)249-304 (1992).30Devlin et al., Aj. J. Psychiatry 157(6):854-866 (2000) "Obesity: what mental health professionals need to know".31Drucker, Diabetes, 47:159-169 (1998).32Edwards et al, Diabetes, 48:86-93 (1998).33Edwards et al., "Glucagon-Like Peptide 1 Has a Physiological Role in the Control of postprandial Glucose in Humans-Studies with the Antagonist Exendin 9-39," Diabetes 48:86-93 (1999).34Edwards et al., "Glucagon-Like Peptide 1 Has a Physiological Role in the Control of postprandial Glucose in Humans—Studies with the Antagonist Exendin 9-39," Diabetes 48:86-93 (1999).35Egan et al., "Glucagon-Like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats," Diabetologia 40(Supp 1):A130 (1997).36Elssele et al., "Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendln-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide," Life Sci., 55:629-34 (1994).37e-Medicine (2008, updated)-http://www.emedicine.com/MED/topic589.htm#sectionAuthorsandEditors, pp. 1 and 3 "Dumping Syndrome".38e-Medicine (2008, updated)—http://www.emedicine.com/MED/topic589.htm#sectionAuthorsandEditors, pp. 1 and 3 "Dumping Syndrome".39Eng et al., "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom," J. Biol. Chem. 267:7402-05 (1992).40Eng et al., "Purification and Structure of Exendin-3 a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom," J. Biol. Chem. 265:20259-62 (1990).41Eng., "Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice," Diabetes 45(Supp 2):152A (abstract 554) (1996).42England, et al.; "Determination of the Packed Cell Volume Using I-Human Serum Albumin"; British Journal of Hermatology, vol. 30; pp. 365-370 (Dec. 1974).43European Patent Application No. 00 928 685: Declaration of Andrew Young filed by Applicants in Proceedings for European Patent Application No. 00 928 685 (Jun. 6, 2008).44European Patent Application No. 00 928 685: European Patent Office Decision to Refuse European Patent Application (Jul. 16, 2008).45European Patent Application No. 00 928 685: Third Party Observations filed in European Patent Application No. 00 928 685 (Apr. 8, 2008).46First Declaration of Mark J. Poznansky attached to Request for Inter Partes Reexamination of US Patent No. 6,924,264.47Francis et al., "PEGylation of cytokines and other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques," Intl J. Hematology 68:1-18 (1998).48Francis et al., "PEGylation of cytokines and other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques," Intl J. Hematology 68:1-18 (1998).49Gaspar et al., Human Mol Genet. 9(13):1957-1966 (2000) "CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation".50Gennaro et al, Remington: The Science and Practice of Pharmacy, 19th Ed., Mack Printing Company, Easton, PA, pp. 1457, 1461, 1526, 1550 (1995).51Gennaro, Ed., Remington: The Science and Practice of Pharmacy, 19th Edition, pp. 898, 931-994 (1995).52Giberman; "Determination of the Trapped Volume in a Pellet of Red Blood Cells"; Section of Biological Ultrastructure, The Weismann Institute of Science, Rehovot (Israel); Experientia, 29: pp. 1083-1085; (Feb. 1973).53Gin et al., Diabetes Metabol. 26(4):2265-272 (2000) "Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes".54Goke et al, Eur. J. Neurosci., 7:2294-2300 (1995).55Goke et al, FEBS Lett., 300:232-236 (1992).56Goke et al, J. Mol. Endocrinol., 2:93-98 (1989).57Goke et al., "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting-Cells," J. Biol. Chem. 268:19650-65 (1993).58Gombotz et al., "Biodegradable Polymers for Protein and Peptide Drug Delivery," Bioconjugate Chemistry 6:332-351 (1995).59Gould; "Diabetes Mellitus Cattle"; Veterinary Record; vol. 109; pp. 539 (Dec. 1981).60Grand, Biochem. J. 258:625-638 (1989).61Grieg et al, Diabetologia, 42:45-50 (1999).62Halaas et al., "weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene" Science 269:543-546 (1995).63Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 53-137 (1988).64Harlow & Lane, Antibodies: A Laboratory Manual, pp. 101, 129 (1988).65 *Heithier et al. (1988) Fluorescent glucagon derivatives. I. Synthesis and characterisation of fluorescent glucagon derivatives. Biochim. Biophys. Acta. vol. 971, pp. 298-306.66Holst, Expert Opin. Emerg. Drugs, 9(1):155-166 (2004).67Hoshino et al, FEBS Lett., 178:233-239 (1984).68Hudecz et al., "Synthesis, Conformation, Biodistribution, and In Vitro Cytotoxicity of Daunomydn-Branced Polypeptide Conjugates," Bioconjugate Chemistry 3:49-57 (1992).69Inter Partes Reexamination of US Patent No. 6,924,264: Petition Under 37 C.F.R. �1.182 for Correction of Second Declaration of Omar Quraishi, filed Jul. 11, 2008.70Inter Partes Reexamination of US Patent No. 6,924,264: United States Patent Office Office Action Closing Prosecution, date Mar. 5, 2009.71Isoai et al, Biochem. Biophys. Res. Comm., 192:7-14 (1993).72Lewis, Hawley's Condensed Chemical Dictionary, 13th Edition, John Wiley & Sons, Inc. (New York), pp. 487, 815 (1997).73Maack, et al.; "Renal Filatration, Transport, and Metabolism of Low-Molecular-Weight Proteins: A Review"; Kidney International vol. 16; pp. 251-270 (Mar. 1979).74Malhotra et al., "Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acid," Regulatory Peptides 41:149-56 (1992).75Mattson et al, Mol. Biol. Reports, 17:167-183 (1993).76Merck Manual Professional (2008, updated): http://www.merck.com/mmpe/sec12/ch159/ch159b.html, pp. 1-2: "Dyslipidemia".77Meurer et al., Properties of native and in vitro glycosylated forms of the glucagons-like peptide-1 receptor antagonist exendin (9-39), Metabolism Clinical and Experimental 48(6):718-724 (1999).78 *Montrose-Rafizadeh et al. (1997) High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J. Biol. Chem. vol. 272, No. 34, pp. 21201-21206.79Montrose-Rafizadeh et al., "High Potency Antagonists of the pancreatic Glucagon-like Peptide-1 Receptor," J. Biol. Chem. 272(34):21201-21206 (1997).80Nordstr�m et al., J. Biotechnol. 69(2-3):125-133 91999).81Nucci et al., The Therapeutic Value of Poly(Ethylene glycol)-Modified Proteins, Adv. Drug Delivery Rev. 6:133-151 (1991).82O'Hagen; "Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration"; J Pharma Pharmacol; vol. 49:pp. 1-10; (Sep. 1997).83O'Halloran et al., "Glucagon-like peptide-1 (7-36)-NH2 : A physiological inhibitor of gastric acid secretion in man," J.Endocrinol 126(1):169-73 (1990).84Orskov et al., "Biological Effects and Metabolic Rates of Glucagordlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Health Subjects are Indistinguishable," Diabetes 42:658-61.(1993).85Orskov et al., "Biological Effects and Metabolic Rates of Glucagordlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Health Subjects are Indistinguishable," Diabetes 42:658-61.(1993).86Parkes et al., Pharmacokinetic Actions of Exendin-4 in the Rat: Comparison with Glucagon-Like Peptide-1, Drug Develop. Res. 5:3260-267 (2001).87Patentee Response to First Office Action issued by the United States Patent Office dated Jan. 17, 2008 for Inter Partes Reexamination of US Patent No. 6,924,264 ; (Apr. 2008).88Pelleymounter et al., Effects of the obese gene product on body weight regulation in ob/ob mice, Science 269:540-543 (1995).89Petrella et al, Diabetes, 48:A425 (1999).90Poznansky & Juliano, Pharmacological Reviews, 36:277-335 (1984).91Poznansky et al, FEBS Lett., 239:18-22 (1988).92Poznansky; "In Vitro and In Vivo Activity of Soluble Cross-Linked Uricase-Albumin Polymers: A Model for Enzyme Therapy"; Life Sciences; vol. 24:pp. 153-158; (1979).93Pratesi et al., "Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug," Brit J. Cancer 52:841-848 (1985).94Praz et al., Regulation of Immunoreactive-Insulin Release from a Rat Cell Line (RINm5F), Biochem. J. 210:345-352 (1983).95Qiagen, Q-proteome Plasma Membrane Protein Handbook (QIAGEN Apr. 2006).96R. Clark, et al., "Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol*," The Journal of Biological Chemistry, vol. 271, No. 36, pp. 21969-21977, 1996.97Raufman et al., "Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive Intestinal peptide receptors and a newly described receptor on dispersed acid from guinea pig pancreas," J. Biol. Chem. 266:2897 (1991).98Raufman et al., "Truncated Glucagon-Like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas," J. Biol. Chem. 267:21432-37 (1992).99Raufman et al., "Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive Intestinal peptide receptors and a newly described receptor on dispersed acid from guinea pig pancreas," J. Biol. Chem. 266:2897 (1991).100Raufman, Regulatory Peptides, 61:1-18 (1996).101Raybould et al., Am. J. Physiol. 274:R1834-R1838 (1998) "Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation".102Reexamination No. 95/000,276; Inter Partes Reexamination of US Patent No. 6,924,264; Second Declaration of Quralshi (May 15, 2008).103Reexamination No. 95/000,276; Inter Partes Reexamination of US Patent No. 6,924,264; Third Declaration of Poznansky (May 15, 2008).104Reexamination No. 95/000,276; Inter Partes Reexamination of US Patent No. 6,924,264; Third Party Requestor's Comments (May 15, 2008).105Remy, et al.; "Immunogenicity and Antigenicity of Soluble Cross-Linked Ensyme/Albumin Polymers: Advantages for Enzyme Therapy"; The Lancet; vol. 2:pp. 68-70 (Jul. 1978).106Request for Inter Partes Reexamination of US Patent No. 6,924,264 filed on Jul. 9, 2007, by ConjuChem Biotechnologies, Inc.107Richter et al, FEBS Lett., 280:247-250 (1991).108Robberecht et al, Biochem. Biophys. Res. Comm., 130:333-342 (1985).109Ruiz-Grande, et al.; Renal Catabolism of Human Glucagon-like Peptides 1 and 2; CAN. J. Physiol. Pharmacol.; vol. 68; pp. 1568-1573 (1990).110Saifer et al., "Improved Conjugation of Cytokines Using High Molecular Weight poly(ethylene glycol): PEG-GM-CSF as a Prototype," Polymer Reprints 38(1):576-577 (1997) (American Chemical Society).111Schepp et al., "Exendin-4 and exendin(9-39) NH2 : agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide 1-(7-36) NH2 ," Eur. J. Pharm. 269:183-91 (1994).112Schirra et al, J. Clin. Invest., 101:1421-1430 (1988).113Schjoldager et al., "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans," Dig Dia Sci 34(5):703-8 (1989).114Schmidtler, Am. J. Physiol., 267:G423-432 (1994).115Second Declaration of Mark J. Poznansky attached to Request for Inter Partes Reexamination of US Patent No. 6,924,264.116Shi, et al.; "Chronic Caffeine Alters the Density of Adenosine, Adrenergic, Cholinergic, GABA, and Serotonin Receptors and Calciuym Channels in Mouse Brain"; Cellular and Molecular Neurobiology; vol. 13, No. 3;pp. 247-261 (1993).117Simonsen et al., Exendin-4, but Not Glucagon-like Peptide-1, is Cleared Exclusively by Glomerular Filtration in Anaesthetised Pigs, Diehetologia 49(4):706-12 (2006).118Singh et al. "Use of 123l-(Y39) exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig," Regul. Pept. 53:47-59 (1994).119Syed et al, Blood, 89:3243-3252 (1997).120Thorens et al., "Cloning and Functional Expression of the Human Islet GLP-1 Receptor-Demonstration that Exendin-4 is an Agonist and Exendin-(9-39) an Antagonist of the Receptor," Diabetes 42:1678-1682 (1993).121Thorens et al., "Cloning and Functional Expression of the Human Islet GLP-1 Receptor—Demonstration that Exendin-4 is an Agonist and Exendin-(9-39) an Antagonist of the Receptor," Diabetes 42:1678-1682 (1993).122Thorens, "Expression cloning of the pancreatic cell receptor for the gluco-Incretin hormone glucagon-like peptide 1," Proc. Natl. Acad. Sci. USA 89:8641-45 (1992).123 *Tota etal. (1995) Interaction of [fluorescein-Trp25]glucagon with the human glucagon receptor expressed in Drosophila Schneider 2 cells. J. Biol. Chem. vol. 270, pp. 26466-26472.124Tsukada et al., An Anti-Fetoprotein Antibody-Deunorubicin Conjugate with a Novel Poly-L-ftutarnic Acid Derivative as Intermediate Drug Carrier, JNCI 73:721-729 (1984).125Tsukada et al., An Anti—Fetoprotein Antibody-Deunorubicin Conjugate with a Novel Poly-L-ftutarnic Acid Derivative as Intermediate Drug Carrier, JNCI 73:721-729 (1984).126Turton et al., A role for glucagon-like peptide-1 in the central regulation of feeding, Nature 379(6560):69-72 (1996).127U.S. Appl. No. 10/913,308, filed Aug. 6, 2004, Coolidge et al.128U.S. Appl. No. 60/037,412, filed Feb. 5, 1997, Drucker.129U.S. Appl. No. 60/103,498, filed Oct. 8, 1998, Coolidge et al.130U.S. Patent Office Communication dated Oct. 3, 2007, regarding Inter Partes Reexamination of US Patent No. 6,924,264.131U.S. Patent Office Non-Final Office Action dated Jan. 17, 2008, regarding Inter Partes Reexamination of US Patent No. 6,924,264.132Vandermeers et al, Eur. J. Biochem., 164:321-327 (1987).133Vandermeers et al, FEBS Lett., 166:273-276 (1984).134Varshavsky, Trends Biochem. Sci., 22(10):383-387 (1997).135Veale et al., "The presence of islet amyloid polypeptide/calcitorin gen-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens," Eur. J. Pharmacol. 262:133-141 (1994).136Wang et al.; Polythylene Glycol-modified Chimeric TOxin Composed of Transforming Growth Factor and Psuedomonas Exotoxin; Cancer Res., vol. 53:pp. 4588-4594 (Dec. 1993).137Wang, et al.; "Parenteral Formulation of Proteins and Peptides: Stability and Stabilizers" J. Paren. Sci. Tech., vol. 42:pp. S3-S26 (1988).138WD (2008,updated): http://www.wrongdiagnosis.com/igt.intro.htm, p. 1 "Impaired glucose tolerance".139Wettergren et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) inhibits Gasteric and Pancreatic Functions in Man," Dig Die Sci 38(4):685-73 (1993).140Willms et al., Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide on Type 2 (noninsulin-Dependent) Diabetic Patients: J. Clin Endocrinol. And Metabolism 81(1):327-332 (1996).141Yeh et al, Proc. Natl. Acad. Sci. USA, 89:1904-1908 (1992).142Zaidi et al., Effects of Copper Chloride Toxicity on Copus Striatum of Rat Brain—A Histological Study, J.Anat.Soc. India 51(1):55-56 (2002).143Zalipsky, "Functionalized Poly (ethylene glycol) for Preparation of Biologically Relevant Conjugates," Bioconjugate Chem. 6:150-165(1995).144Zimmerman et al.; "Schedule Dependency of the Antitumor Activity and Toxicity of Polythylene Glycol-modified Interleukin 2 in Murine Tumor Models"; Cancer Res., 49:6521-6528 (Dec. 1989).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8445647Nov 14, 2011May 21, 2013Amylin Pharmaceuticals, LlcModified exendins and exendin agonistsUS8951962May 17, 2013Feb 10, 2015Amylin Pharmaceuticals, LlcModified exendins and exendin agonistsUS9089538Apr 27, 2011Jul 28, 2015Zealand Pharma A/SPeptide conjugates of GLP-1 receptor agonists and gastrin and their useUSRE45313Jul 17, 2013Dec 30, 2014Zealand Pharma A/SExendin variant peptidesClassifications U.S. Classification424/489, 530/300, 424/278.1, 514/6.9, 514/4.9International ClassificationA61K38/22, A61K38/00, A61K9/14, A61K47/48, C07K14/47Cooperative ClassificationA61K47/48215, C07K14/605European ClassificationA61K47/48K6PLegal EventsDateCodeEventDescriptionOct 28, 2005ASAssignmentOwner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRICKETT, KATHRYN S.;YOUNG, ANDREW A.;SIGNING DATES FROM20051003 TO 20051026;REEL/FRAME:016703/0008Mar 22, 2006ASAssignmentOwner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRICKETT, KATHRYN S;YOUNG, ANDREW A;REEL/FRAME:017345/0973Effective date: 20001218Apr 16, 2008ASAssignmentOwner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRICKETT, KATHRYN S.;YOUNG, ANDREW A.;REEL/FRAME:020836/0230;SIGNING DATES FROM 20051003 TO 20051026Owner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRICKETT, KATHRYN S.;YOUNG, ANDREW A.;SIGNING DATES FROM20051003 TO 20051026;REEL/FRAME:020836/0230Apr 29, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services